Works Cited

1. Gervasini G, Benítez J, Carrillo J. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.Eur J Clin Pharmacol. 2010;66(8):755-774.

2. Wu AH. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing.Arch Pathol Lab Med. 2013;137(9):1232-1236.

3. Kim S, Yun YM, Chae HJ, et al. Clinical pharmacogenetic testing and application: laboratory medicine clinical practice guidelines.Ann Lab Med. 2017;37(2):180-193.

4. Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage?Br J Clin Pharmacol. 2012;74(4):698-721.

5. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing.Clin Genet. 2012;82(4):388-394.

6. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict therapeutic dose of warfarin.Clin Pharmacol Ther. 2008;84(3):326-331.

7. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphism and response to clopidogrel.N Engl J Med. 2009;360(4):354-362.

8. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Breast Cancer Res Treat. 2007;101(1):113-121.

9. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Pharmacogenomics. 2006;7(8):1211-1221.

10. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte: an update of guidelines.Clin Pharmacol Ther. 2011;89(5):662-673.

11. Pop TR, ChirităDN, Buzoianu AD. Pharmacogenetics of oral anticoagulant therapy.Hum Vet Med. 2013;5(1):9-13.

12. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests.Clin Pharmacol Ther. 2009;86(1):109-113.

13. Hood E. Pharmacogenetics: the promise of personalized medicine.Environ Health Perspect. 2003;111(11):A581-A589.

14. Hoop JG, Lapid MI, Paulson RM, Roberts LW. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in three "early adopting" departments of psychiatry.J Clin Psychiatry. 2010;71(6):745-753.

15. Haga SP, Burke W. Pharmacogenetic testing: not as simple as it seems.Genet Med. 2008;10(6):391-395.

16. Carrieri D, Bewshea C, Walker G, et al. Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting report.J Med Ethics. 2016;42(11):695-697.

17. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome.N Engl J Med. 2005;353(2):133-144.

18. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res.2006;12(13): 3908-3914.

19. Cavallari L, Shin J, Perera, MA. Role of pharmacogenetics in the management of traditional and novel oral anticoagulants.Pharmacotherapy. 2011;31(12):1192-1207.

20. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups.Blood. 2010;115(18):3827-3834.

21. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.Clin Cancer Res. 2007;13(12):3731-3737.

22. Cecchin E, Agostini M, Pucciarelli S, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.Pharmacogenomics J. 2011;11(3):214-226.

23. Dreussi E, Cecchin E, Polesel J, et al. Pharmacogenetics biomarkers and their specific role in neoadjuvant chemoradiotherapy treatments: an exploratory study on rectal cancer patients.Int J Mol Sci. 2016;17(9):1482.

24. Vogenberg FR, Barash CI, Pursel M. Personalized medicine, part 2: ethical, legal and regulatory issues.P T.2010;35(11):624-626, 628-631, 642.

25. Barash CI. Ethical Issues in Pharmacogenetics. Available at http://www.actionbioscience.org/biotechnology/ethical_issues_in_pharmacogenetics.html. Last accessed March 26, 2018.

26. American Academy of Pediatrics. Ethical and policy in genetic testing and screening of children.Pediatrics. 2013;131(3):620-622.

27. Brice P, Sanderson S. Pharmacogenetics: What are the Ethical and Economic Implications? Available at https://www.pharmaceutical-journal.com/news-and-analysis/news/pharmacogenetics-what-are-the-ethical-and-economic-implications/10001689.article. Last accessed March 26, 2018.

Evidence-Based Practice Recommendations Citations

1. Schaefer GB, Mendelsohn NJ, Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions.Genet Med. 2013;15(5):399-407. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/47137. Last accessed April 2, 2018.



Privacy Policy
Copyright © 2018 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.